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MicroarraySjögren's syndrome is a chronic autoimmune disease characterized by lymphocytic inﬁltration of the salivary
and lachrymal glands resulting in dry eyes and mouth. Genetic predisposition, pathogenic infections and hor-
mones have been implicated in the pathogenesis of the disease. Studies in the last several years have revealed
marked over-expression of the type I interferon (IFN)-inducible genes in the peripheral blood and salivary
glands of patients with Sjögren's syndrome. The expression of the type I IFN-inducible genes in Sjögren's
syndrome also positively correlates to titers of anti-Ro and anti-La autoantibodies, which are typical for this
disease. Plasmacytoid dendritic cells (pDC) are the major source of type I IFN production and activated pDC
are detected in minor salivary gland biopsies from patients with primary Sjögren's syndrome. In addition, poly-
morphisms in genes important both for the production and response to type I IFN are associated to increased risk
for Sjögren's syndrome. Because type I IFN bears a variety of biological functions, such as defense against viral
infections and activation of the immune system, these results suggest that the type I IFN systemhas an important
role in the pathogenesis of Sjögren's syndrome. A variety of mechanisms causing an activation of the type I IFN
system are discussed in this review. Given the pivotal role of type I IFN in the disease process, therapeutic
interventions targeting the type I IFN signaling pathway have the potential to beneﬁt the patients with elevated
type I IFN status and such hypothesis needs to be carefully evaluated in clinical development.
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-ND license.1. Introduction
Sjögren's syndrome is named after Henrik Sjögrenwho reported de-
tailed clinical and histological ﬁndings in 19 women with xerostomia
and keratoconjunctivitis sicca in his dissertation in 1933 [1]. Sjögren's
syndrome is a chronic autoimmune disease characterized by mono-
nuclear cell inﬁltration of exocrine glands, particularly, salivary and
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function. The clinical consequences of Sjögren's syndrome are typically
dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia).
Besides these, Sjögren's syndrome also exhibited systemic features of
autoimmune diseases as it progress in multiple organs such as lung,
liver, kidney, vascular, gastrointestinal and nervous systems [2–6].
Many patients may also experience fatigue and pain in joints and
muscle. A variety of studies have shown that a portion of Sjögren's
syndrome patients exhibited an ongoing B-cell hyperactivity which
maybe associatedwith an increased incidence of lymphoidmalignancies
[7–9]. Sjögren's syndrome can occur alone, deﬁned as primary Sjögren's
syndrome (pSjS), or together with almost any other autoimmune
disease, but most frequently with rheumatoid arthritis (RA) or SLE,
thus deﬁned as secondary Sjögren syndrome. Such overlap connective
tissue diseases have recently been reviewed by Iaccarino et al. [10].
pSjS affected approximately 0.1–0.4% of the general population with
large female preponderancewith ratio of female:male about 9:1 [11–14].
In this review, we mainly focus on pSjS.
2. Pathogenesis of Sjögren's syndrome
The common feature of affected organs in Sjögren's syndrome
is periepithelial lymphocytic inﬁltration which eventually leads to
dysfunction of the affected organs. The salivary glands are the most
studied organs as they are affected in almost all the patients and
easily accessible for clinical and experimental tests. The hallmark of his-
topathological ﬁndings is generally the progressive focal inﬁltration of
mononuclear cells, replacing glandular epithelium (lymphoepithelial
lesion) [15]. In a recent report, Christodoulou et al provided a compre-
hensive survey regarding the composition of inﬁltrated cell types and
its association with the lesion severity. Their results showed that the
distribution of inﬁltrating mononuclear cells at the lesions of Sjögren's
patients varied according to lesion severity and correlated with disease
manifestations by staining of minor salivary gland (MSG) biopsies
[16]. The percentage of different immune cell populations among the
total inﬁltrated mononuclear cells were signiﬁcantly different among
MSG tissues with mild, intermediate or severe inﬂammatory lesions;
total T cell, CD4+ T cell, T/B cell ratio and iDC incidences were nega-
tively, whereas B cell and macrophage incidences were positively
correlated with inﬁltration grade and biopsy focus scores [16]. Tregs
were found to be predominant in intermediate lesions and were also
observed to be correlated with the grade of the autoimmune lesion
and certain adverse prognostic factors such as the presence of C4
hypocomplementemia and salivary gland enlargement [20,21]. In-
creased macrophages and dendritic cells were also observed in MSGs
from patients with Sjögren's syndrome but not from non-Sjögren's
syndrome disease control subjects, particularly in B cell rich areas
and in germinal center-like structures in patients. They may correlate
with adverse predictors of lymphoma development [22]. A recent
study by Theander et al. indicated that the germinal center-like lesions
in labial salivary gland biopsies taken at pSjS diagnosis was highly
predictive of the risk of non-Hodgkin's lymphoma (NHL) development
[23]. Both of the inﬁltrated T and B lymphocytes at salivary gland are
activated as surface markers for activation, MHC class II molecules,
IL-2 receptors, were observed to be expressed [17]. In addition, the in-
ﬁltrated and activated plasma cells in MSG secreted immunoglobulins
with isotypes mainly of IgG and IgM, whereas in normal salivary
glands, IgA is the dominant isotype [18]. In a recent report, Varin et
al. showed that in Sjögren's syndrome, B lymphocytes were associated
with direct tissue damage by inducing epithelial cells of salivary glands
into apoptosis through protein kinase C delta activation [19]. In
fact, the principal characteristic feature of Sjögren's syndrome is the
presence of a variety of autoantibodies directed against organ or
systemic non-organ autoantigens. Antinuclear antibodies are present
in the sera of 80% of patients. Among them, two antibodies targeting
ribonucleoproteins, Sjögren's syndrome antigen A (Ro) and Sjögren'ssyndrome antigen B (La) are included in the ofﬁcial criteria for diag-
nosis of Sjögren's syndrome [20–22]. These two autoantibodies, how-
ever, also exist in other autoimmune diseases, such as systemic lupus
erythematosus (SLE). Other autoantibodies such as anti-annexin
autoantibodies have been found with the potential as biomarkers
for autoimmune diseases [23]. Among anti-annexin autoantibodies,
anti-annexin XI antibody was observed in Sjögren's syndrome. Anti-
bodies to SSA antigen (Ro52/Ro60), are now known to consist of two
different proteins coded by distinct cDNAs and isolated anti-Ro52 anti-
bodies showed high prevalence in autoimmune diseases including
Sjögren syndrome [24]. Autoantibodies possess important diagnostic
and prognostic value in assessing disease activity in autoimmune
diseases. In a recent report, Racanelli et al. reviewed the different lines
of research which are presently being conducted to understand how
these autoantibodies are generated (e.g. through apoptotic body
formation, molecular mimicry and other mechanisms) and cellular lo-
cations where they target self antigens to cause an autoimmune dis-
ease [25].
Several studies have also suggested that glandular or acinar epi-
thelial cells play an important role in the pathogenesis of Sjögren's
syndrome as they may actively participate in the induction and per-
petuation of the inﬂammatory process at disease sites [26]. Epithelial
cells at disease sites of Sjögren's syndrome showed elevated expression
of stimulatory molecules, such as CD40, B7 and adhesion molecules, as
well as lymphoid chemokines and BAFF, suggesting the potential role
of epithelial cells in attracting and activating DCs, T cells and B cells in
the inﬂammatory glandular tissues [26–30].
Interestingly,most human autoimmune diseases including Sjögren's
syndrome have increased incidence and prevalence in females. Sex
hormones may preset the susceptible environment for subjects and
inﬂuence humoral and cell-mediated immune responses. Experiments
in animal models suggested a role for estrogen deﬁciency in Sjögren's
syndrome andmay indicate that estrogen deﬁciency stimulates salivary
epithelial cells to present autoantigen to the CD4+ T cells to induce
lesions in the salivary glands, which resemble those of human Sjögren's
syndrome [31,32]. Data from both human and autoimmune animal
studieswere recently reviewed to determine reasons for sex differences
in autoimmune disease [33]. Another sex hormone, Prolactin (PRL) was
reported to regulate immune response and be able to stimulate auto-
immunity and to be associated with a variety of autoimmune diseases
including pSjS [34].
Although the accumulating evidences conﬁrmed the inﬁltration and
activation of inﬂammatory cells at biopsies of affected glandular organs,
the mechanisms that generate, attract and activate these autoreactive
cells at disease sites still remain unclear. It has been hypothesized that
in genetically susceptible subjects, environmental stimuli, viral infec-
tion or hormonal aberration all could result in generating autoreactive
lymphocytes and induce autoimmune attack on glandular organs. See
Section 5 for a more comprehensive discussion.
3. Type I IFN in Sjogren's syndrome
3.1. Activated type I IFN in autoimmune diseases
The type I interferon (IFN) family consists of multiple members
including IFN-α, -β, -ε, -κ, -ω, -δ, and -τ [35,36]. They bear a variety
of biological functions, such as defending against viral or bacterial
infection, immuno-modulation, and anti-proliferation. Due to their
pluripotent function, type I IFNs, more speciﬁcally IFN-α/β have
been intensively studied for decades for their important roles in
immunity/autoimmunity and cancers. Although IFN-α/β can be
produced by many types of cells when exposed to environmental
threats such as viral or bacterial infections, the most potent source
of IFN-α/β production is plasmacytoid dendritic cells (pDCs), which
produce more than 1000-fold IFN-α/β than any other cell type
[37–39]. Activated type I IFN signaling pathway will induce the
560 Y. Yao et al. / Autoimmunity Reviews 12 (2013) 558–566expression of a large number of antiviral genes which exhibit direct
antiviral function by degradation of viral RNA, inhibition of translation
of viral mRNA, induction of harmful mutations in the reproducing
virus or apoptosis of infected cells. Type I IFN can also enhance the cy-
totoxicity of NK cells and CD8+ T cells, promote antibody production
by B cells as well as development and maturation of macrophage
[35,40]. Accumulating evidence has shown that activated type I IFN
pathway played an important role in autoimmune diseases [41–49].
A recent study using immunohistochemistry, enzyme-linked immu-
nosorbent assay (ELISA), and real-time PCR to measure type I IFN
expression at transcript or protein levels at labial salivary gland biopsy
specimens, plasma, and peripheral blood cells from patients with
pSjS showed that IFN-α expression levels are all up-regulated in
patients with pSjS in labial salivary glands, plasma and peripheral
blood cells [50].
3.2. Genetic factors associated with type I IFN activation
Genetic predisposition to Sjögren's syndrome was supported by
the evidence of familial aggregation, animal models and candidate
gene association studies [51]. The major histocompatibility complex
(MHC) region is the most susceptible loci for onsets of autoimmune
diseases [52–54]. A recent large scale meta analysis world wide of
HLA and Sjögren's syndrome susceptibility further stressed the signif-
icant size effect HLA exhibited in the development of pSjS [55].
Besides that, many other risk genes were also identiﬁed from various
studies. For example, gene expression proﬁling approach has un-
veiled a common dysregulation of the type I IFN pathway in clinically
distinct diseases such as SLE, Sjögren's syndrome, dermatomyositis,
and psoriasis [56]. Therefore, genetic studies in SLE may provide
additional insight into potential genetic contributions to pSjS. Poly-
morphism of IRF5 (interferon regulatory factor) is important for
transactivation of type I IFN and IFN inducible genes [57,58] and
was shown to be associated with SLE [59,60]. Sigurdsson et al. revealed
a novel CGGGG insertion–deletion (indel) polymorphism of IRF5 and
the CGGGG indel contains three or four repeats of the sequence
CGGGG with the longer allele (four repeats of CGGGG) as the risk allele
for SLE. This risk allele is associated with increased expression of IRF5
mRNA from minigene constructs and increased protein level observed
in peripheral blood mononuclear cells from SLE patients [60]. In addi-
tion, the same IRF5 allele was also found to confer risk for inﬂammatory
bowel diseases andmultiple sclerosis, suggesting a general role for IRF5
in autoimmune diseases [60]. Recently, its signiﬁcant association with
Sjögren's syndrome was conﬁrmed by Miceli-richard et al. in studying
212 pSjS patients and 162 healthy controls [61]. An association of the
CGGGG insertion/deletion polymorphism of the IRF5 promoter with
pSjSwas identiﬁed. Patients carrying the four repeats CGGGG IRF5 allele
showed a high level of mRNA for IRF5 in PBMCs and salivary gland
epithelial cells which were correlated with the levels of mRNA for
the IFN inducible genes, MX1 and IFITM1 [62]. In addition, Nordmark
et al. investigated the association of the three major polymorphisms
(the longer allele, four repeats of CGGGG, of the CGGGG indel in IRF5,
the C-allele of the SNP rs10488631 in IRF5 and the C-allele of the SNP
rs7582694 in STAT4) in IRF5 and STAT4 with pSjS. Interestingly, this
study not only revealed the strong signals for association between all
three polymorphisms and pSjS but also discovered an additive manner
of these three risk alleles with regard to developing pSjS, which was
clearly exhibited by linear regression analysis. These genetic studies
provide ﬁrst line evidence supporting that genetic susceptibility may
be fundamental for aberrantly activated type I IFN pathway upon envi-
ronmental stimuli to induce onset of Sjögren's syndrome.
3.3. Environmental factors associated with type I IFN activation
Environmental factors mainly refer to the infections at glandular
tissues, which may prompt epithelial cells to activate the innateimmunity system through Toll-like receptors (TLR) pathways. TLRs
recognize conserved molecular patterns shared by micro-organisms
and products of apoptosis of cells, such as TLR3 recognizing double
strands RNA, TLR4 recognizing LPS, TLR7 recognizing single strand
RNA and TLR9 recognizing unmethylated CpG DNA, and induce the
production of inﬂammatory cytokines including type I IFN and
upregulation of co-stimulatory and adhesion molecules [63]. The in-
fections at salivary gland by those viruses or other micro-organisms
lead to elevated type I IFN production by pDCs, and to apoptosis
or necrosis of glandular epithelial cells exposing the autoantigens
to autoantibodies inducing the autoimmune responses [64]. A num-
ber of infectious agents such as Epstein–Barr virus (EBV), human
T-lymphotropic virus type 1 (HTLV-1), hepatitis C virus, and enterovi-
rus have been reported to be potential initiators for glandular lesions
of patients with Sjögren's syndrome [65]. Interestingly, EBV is found
to be a common virus in Sjögren's syndrome patients with high
incidence [66–68]. It may infect both salivary epithelial cells and B
cells [69] although how response to EBV infection induces lesions of
Sjögren's syndrome is still unknown.
4. Type I IFN-inducible transcripts in Sjögren's syndrome
Type I IFN in serum or plasma is usually difﬁcult to measure via
traditional ELISA based techniques [46,70,71]. The development of
highly sensitive cell reporter assays permitted the demonstration of
the presence of detectable type I IFN activity in the sera or plasmas
of pSjS [72,73]. However, even with more sensitive assays such as
the Gaussia luciferase reporter gene activation assay [74], results of
measuring low levels of type I IFN are far from consistent. In contrast
to directly measuring the protein level of type I IFN, measuring type I
IFN-inducible transcripts provide a more consistent and sensitive
alternative evaluation for the activation of the type I IFN pathway. Our
internal study comparing the results of using type I IFN-inducible tran-
scripts and the Gaussia luciferase reporter assay to measure the type I
IFN activity in the peripheral blood of 144 SLE patients shows that
only a fraction of SLE patients that are type I IFN signature positive
have detectable type I IFN protein in the serum; and all SLE patients
that are type I IFN protein positive are also type I IFN signature positive.
And furthermore, SLE patients that are type I IFN protein positive are
among those with the highest type I IFN gene signature scores [75].
An approach such as ex vivo stimulation of healthy donor whole
blood or peripheral blood mononuclear cells (PBMCs) with type I IFN
subtypes coupled to transcript-level proﬁling provides a relatively
complete understanding about the transcripts that are inducible by
the type I IFN [46,47,76]. Early applications of type I IFN-inducible tran-
scripts showed utility as a robust marker of activation of the type I IFN
pathway in systemic lupus erythematosus (SLE), as well as a surrogate
for IFN-α/β levels in the serum [46,47,77]. Several studies have also
demonstrated how the type I IFN signature is both speciﬁc and unique
to type I IFN instead of to type II IFN [45,48,77].
Besides SLE, genome wide transcript proﬁling studies have also
revealed marked over-expression of type I IFN inducible genes in
the peripheral blood of patients with dermatomyositis (DM), poly-
myositis (PM), RA, systemic sclerosis (SSc), and Sjögren's syndrome
[41,48,78,79]. And it was further shown by Higgs et al. that patients
with SLE, DM, PM, RA and SSc share activation of a common type I IFN
pathway [45]. Furthermore, this type I IFN signature was also observed
in the disease tissues of multiple autoimmune diseases including skin
lesion and synovial tissues of SLE patients [80,81], muscle lesions of
myositis patients [42,43,46], and skin lesion of SSc patients [45,82,83].
A concordant activation of the type I IFN pathway in the peripheral
blood and disease-affected tissues was identiﬁed in SLE, DM, PM and
SSc, and this signature was positively correlated with disease activities
in SLE, DM, PM, and SSc [41,45,46,84–86].
An example of type I IFN-inducible gene expression in subjects
with pSjS or controls was shown by Gotternber et al. [87]. Interestingly,
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pSjS, B cell-activating factor (BAFF), was found to be induced under
the stimulation of IFN-α in salivary gland epithelial cells (SGECs), the
main targets of autoimmunity in pSjS, while not induced in controls.
These results suggested that SGECs of patients with pSjS were particu-
larly susceptible to expressing BAFF under IFN-α stimulation [88] and
demonstrated the pivotal role of type I IFN in activating B cells at disease
sites of Sjögren's syndrome. The elevation of the type I IFN gene signa-
ture in pSjS was further conﬁrmed by Emamian et al. [89]. In their
study, type I IFN gene signature was ﬁrst identiﬁed in a training set of
PBMC of 21 Sjögren's syndrome cases and 23 healthy controls. It was
then validated in an independent set of PBMC of 17 Sjögren's syndrome
patients and 22 healthy controls. Interestingly, when examined for
relationships to clinical features of disease, Emamian et al. found that
expression levels of most type I IFN inducible genes were signiﬁcantly
positively correlated with titers of anti-Ro/SSA and anti-La/SSB auto-
antibodies. These associations suggested that diagnostic and thera-
peutic approaches targeting type I IFN signaling pathway might be
more suitable for Sjögren's syndrome patients with elevated levels of
anti-Ro/SSA and anti-La/SSB autoantibodies.
5. Sources and induction of type I IFN in Sjögren's syndrome
As the most potent producer of type I IFNs, pDCs have been
observed to inﬁltrate affected tissues and produce large amount of
type I IFN in various autoimmune diseases [38,90–93]. This implies
that the original source of type I IFN which activated down-stream
gene expression found from these tissues is likely from affected
disease sites, rather than peripheral blood. Activated pDCs have
been shown to accumulate in disease tissues of several autoimmune
diseases such as skin lesions and/or joints of SLE and SSc patients
[82,90,92], synovial ﬂuid of RA patients [94], and muscle and skin
lesions of DM patients [42,95,96]. The presence of IFN-α containing
cells in MSG biopsies from patients with pSjS provided the ﬁrst evi-
dence that pDCs indeed participate in formation of inﬂammatory
foci [43]; Identiﬁcation of pDC in salivary glands of patients with
pSjS, but not in non-Sjögren's syndrome disease controls was further
conﬁrmed by Gotternberg et al. by staining with pDC surface markers,
CD123 and BCDA2 [87]. By contrast, the number of circulating pDCswas
signiﬁcantly less in the peripheral blood as compared with those of
normal healthy controls [38,97], a similar observation that was ob-
served in SLE [98]. These results implied that the pDCs migrated from
periphery to the involved tissues, such as salivary or lacrimal glands
[79,99] in patients with pSjS; similarly, the recruitment of pDCs from
periphery to affected tissues in patients with SLE was proposed [97].
pDCs may play a similarly important role in the disease pathogenesis
of Sjögren's syndrome as that in SLE.
The utility of diagnosing primary Sjögren's syndrome with minor
salivary gland biopsy was recently reviewed [100], and gene expres-
sion proﬁling of minor salivary gland biopsy may provide relevant
information with regard to disease pathogenesis. Microarray based
transcript proﬁling analysis have revealed elevated expression of
type I IFN-inducible genes in biopsies of minor salivary glands from
patients of Sjögren's syndrome [44] as well as in monocytes isolated
from peripheral blood [79]. However, the source of the circulating
type I IFN in pSjS remains unknown, and there has been no direct
analysis to determine the association of type I IFN expression be-
tween gland tissues and peripheral blood reported in the literature.
On the other hand, signiﬁcant positive correlations of type I IFN
gene signature between involved tissues and peripheral blood were
observed in several autoimmune diseases [45], indicating that the
elevated expression of type I IFN inducible genes in peripheral blood
in these diseasesmay result from type I IFN produced by the inﬁltrated
pDC at affected tissues [45]. A recent report showed that circulating
pDCs in pSjS patients displayed increased expression of CD40, and it
was correlated with the expression level of the type I IFN induciblegenes IFI27 and IFITM1 in monocytes of the same individuals [79].
These results suggested that the increased type I IFN activity observed
in pSjS might result not only from production of inﬁltrated pDC at in-
ﬂammatory glandular tissues but also from the remaining activated
pDC in peripheral blood. Besides pDCs, recent data from animal models
suggested that salivary epithelial cells might be another source for
type I IFN production in Sjögren's syndrome. Repeated stimulation of
poly (I:C) in female NZM F1 mice resulted in elevated expression of
TLR3, and rapid up-regulation of the mRNA levels of type I IFN and
inﬂammatory cytokines in the submandibular glands [101]. Given the
evidence that expression of TLR3 was also identiﬁed in salivary epithe-
lial cells from patients with Sjögren's syndrome, the salivary gland
epithelial cells activated by TLR3 may be another source of type I IFN
in affected gland tissues [102].
Bave et al. showed that apoptotic cells of the myeloid leukemia
cell line U937 as well as four other cell lines (MonoMac6, H9, Jurkat,
and U266) could induce IFN-α production in PBMC when combined
with IgG from SLE patients [103]. This study ﬁrst demonstrated that
endogenous products from apoptotic cells were the potential triggers
for type I IFN production. With further investigation, Bave et al. found
that sera from patients with pSjS or SLE combined with apoptotic
or necrotic cells could induce IFN-α production by pDC; the
prolonged IFN-α synthesis at tissue level of pSjS was probably caused
by RNA-containing immune complexes activating pDCs [43]. Lövgren
et al. have provided additional evidence that SLE or Sjögren's syndrome
autoantigen-associated U1 small nuclear RNA (U1 snRNA) and hY1RNA
have IFN-α inducing capacity; immune complexes containing such
RNA, for example, U1 snRNP particles, can induce IFN-α production by
pDC, indicating such immune complexes at least partly contributing to
the ongoing IFN-α production seen in SLE and Sjögren's syndrome
[104]. Interestingly, a major antigenic target for both Sjögren's syn-
drome and SLE, Ro52 consisting of ribonucleoprotein complex, can be
up-regulated and can translocate to the nucleus upon stimulation of
IFN-α [105]. This result is in line with a report by Emamian et al. that
levels of type I IFN inducible genes were signiﬁcantly positively corre-
lated with titers of anti-Ro/SSA and anti-La/SSB autoantibodies [89]
(see Section 4). The up-regulated autoantigens may induce more auto-
antibody production and form more immune complexes to induce
more IFN-α synthesis and result in expression of type I IFN inducible
genes. Thus, a reciprocal stimulation feedback loop may be established
between IFN-α production and immune complex formation which
will amplify the effect of activated type I IFN system on onset or per-
petuation of Sjögren's syndrome.
Bacterial genomes are characterized by unmethylated CpG stimu-
latory motif that can activate pDCs to produce type I IFN through TLR9
receptor. Under normal condition, mammalian DNA is characterized
by methylated CpG non-stimulatory motifs; interestingly, molecular
analysis of DNA isolated from plasma from patients with SLE
had shown distinct patterns from human genomic control DNA
[106–108], implying that such speciﬁc DNA may have the potential
to induce type I IFN production by pDCs. Similar mechanisms have
yet to be examined in patients with Sjögren's syndrome. Endogenous
retrotransposon L1 elements could represent a viral-like stimulus for
type I IFN pathway activation, which could provide a dual trigger for
activation of pDCs and type I IFN production by TLR9 binding of
its CpG rich DNA and/or by its transcribed L1 mRNA through TLR7
activation [109]. A report by Mavragani et al. showed that increased
L1 mRNA expression was detected in MSG tissue from pSjS patients
compared with MSG tissue from healthy and non-autoimmune con-
trols [110]. In addition, a strong correlation was observed between
full-length L1 and IFN-α2 mRNA expression in MSG from patients
of Sjögren's syndrome. In vitro stimulation of pDCs with an L1
containing plasmid also exhibited a dose dependent increase of
IFN-α [110].
Both extracellular and intracellular nucleic acids can induce type
I IFN production through endosomal and cytosolic sensors,
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endosomal Toll-like receptors, such as TLR3, TLR7, and TLR9 as de-
scribed in above and Section 3.3; cytosolic nucleic acids are sensed
by ubiquitously expressed cell-intrinsic receptors and further induce
type I IFN production [112–115]. TREX1 (DNaseIII) is the ubiquitously
expressed human 3′–5′ exonuclease; normal function of this gene
product is required to dispose of endogenous nucleic acids that
might otherwise stimulate an innate immune response including in-
ducing elevated production of type I IFN [112,113]. Loss of function
mutations in the human TREX1 gene cause Aicardi–Goutieres Syn-
drome (AGS) with phenotype of elevated type I IFN levels in cerebro-
spinal ﬂuid [114]; mutations of TREX1 have been recently linked to
SLE and Sjögren's syndrome [115,116]. Studies inmicewith deﬁciency
of TREX1 showed that an accumulation of ssDNA derived from endog-
enous retroelements including L1 elements discussed above, otherwise
degraded by functional TREX1, was responsible for the increased pro-
duction of type I IFN in this strain [113]. This evidence supports that
TREX1may be a negative regulator for type I IFN production through cy-
toplasmic cell-intrinsic DNA signaling pathway [117–119], and dys-
function or mutation of TREX1 may result in aberrant expression of
type I IFN and autoimmune disorders such as Sjögren's syndrome.
Recently, a neutrophil signature was reported to be present in the
blood of a fraction of SLE patients [46,70]. Several research groups
have proposed that NETosis, a particular type of neutrophil cell
death, may play an important role in chronically activating pDCs
thus helping to maintain the persistently elevated type I IFN level in
patients with SLE as well as stimulating autoantibody production
[120–123]. NETosis is characterized by the active release of nuclear
chromatin ﬁbers into the extracellular space to form a web-like struc-
ture called neutrophil extracellular traps (NETs) [124,125]. NETosis
was associated with organ involvement in SLE and the expression
of several neutrophil speciﬁc genes was shown to be correlated
with disease activity as measured by SLEDAI [46]. Considering the
similarity between SLE and Sjögren's syndrome with regard to the
involvement of elevated expression of type I IFN in disease pathogen-
esis, NETosis, which may provide sources for DNA or RNA containing
immune complex for inducing the type I IFN production by activating
pDCs, could be one of the potential triggers of type I IFN production
in pSjS. That said, this hypothesis is speculative at the moment and
needs to be conﬁrmed in pSjS.
6. Epigenetic control of type I IFN in Sjögren's syndrome
Epigenetics is deﬁned as stable and heritable changes of gene ex-
pression which was not involved in alternations of DNA sequences.
Epigenetic factors including DNA methylation and histone modiﬁca-
tions have been shown to be associated with cancers, autoimmune
diseases, heart diseases and skin diseases [126]. Autoimmunity related
epigenetic modiﬁcations have been reported in SLE and RA [127–131].
It has been shown that DNA conformation and post-translational
modiﬁcation, such as ubiquitin modiﬁcation, could affect antigenicity
and immunogenicity. Ro52 is the target for autoimmune responses
in pSjS. Ro52 was found conjugated with poly-ubiquitin chain in
cells; and interestingly, sera from patients with Sjögren's syndrome
showed heterogeneity in their reactivity to poly-ubiquitinated Ro52,
probably because of their differing antigenic determinants. This
heterogeneity of the reactivity might be associated with the varying
clinical features found in patients with Sjögren's syndrome [132] and
may also result in a different immune complex with different ability
to induce type I IFN production (see Section 5). Phosphorylation of
the major B-cell epitope of La/SSB was also found to possess higher
avidity to anti-La/SSB antibodies in serum of patients with pSjS or
SLE [133].
As discussed earlier in Section 5, endogenous L1 element is the po-
tential activator of the type I IFN pathway in MSG tissues of Sjögren's
syndrome patients. Mavragani et al. tried to determine if thereis epigenetic regulation of endogenous L1 retroelement in pSjS in re-
sponse to the activated type I IFN [134]. Methylation of promoter of
genes is a major mechanism for suppression of gene expression.
Over-expression of all members of methylation machinery including
DNA methyltransferases, DNMT1, DNMT3A and DNMT3B, are detected
in Sjögren's syndrome MSG tissues compared with those of pool of
healthy controls. Concordant expression of methylation enzymes such
as DNMT3B, MeCP2 and DNMT1 with L1 element expression was
also observed in MSG tissues of Sjögren's syndrome patients [134].
This over-expression of epigenetic regulatory machinery may reﬂect a
compensatory feedback to restrict the type I IFN production through
controlling expression of L1 element in Sjögren's syndrome.
7. miRNAs and type I IFN pathway in Sjögren's syndrome
MicroRNAs are endogenous non-coding, small RNAs (19 to 21
nucleotide-long oligonucleotides) that interfere with or affect the
transcription or translation of other genes, resulting in gene silencing
or activation by a process known as RNAi or RNA activation, respec-
tively and are important in a wide range of physiological and patho-
logical processes [135]. Given the pivotal role for controlling gene
expression, microRNA are also key regulators in immune system
development and maintain its normal function such as controlling
T cell and B cell differentiation in the thymus and bone marrow,
and subsequent peripheral homeostasis; and aberrant regulation of
microRNA may result in autoimmunity [136]. A variety of microRNAs
have been implicated in human autoimmune diseases. For example,
miR-326 that regulates Th17 cell was signiﬁcantly over-expressed in
peripheral blood of patients with relapsing remitting form of multiple
sclerosis [80]. MiR-146a, induced by TNF-α and IL-1β, was highly
expressed in human RA synovial tissues [137]. On the other hand,
miR-146a was under-expressed in the peripheral blood of SLE pa-
tients and its expression was negatively correlated with both clinical
disease activity and the type I IFN signature scores in SLE [138]. Fur-
thermore, overexpression of miR-146a reduced, while inhibition of
endogenous miR-146a increased, the induction of type I IFNs in nor-
mal PBMCs [138]. These results suggested that underexpression of
miR-146a in SLE patients interferes with the type I IFN production
by targeting the key signaling proteins that regulate the type I IFN
signaling pathway [138]. Interestingly, Pauley et al. recently found
that the expression of miR-146a was signiﬁcantly increased in the
PBMC of Sjögren's syndrome patients bymore than 7.9-fold compared
with healthy controls [139]. miR-146a was upregulated in the salivary
glands and PBMC of the Sjögren's syndrome prone mouse model,
C57BL/6.NOD-Aec1Aec2, either prior to or after disease onset. Further-
more, no correlation between miR-146a expression and type I IFN
inducible gene expression was observed [139]. The discrepancy of
miR-146a expression and its relation to type I IFN production between
Sjögren's syndrome and SLE is interesting given the similar patholog-
ical role of type I IFN in both diseases andmore studies need to be car-
ried out to unveil the molecular mechanism behind the observations.
One possible explanation to such discrepancy is that more than one
miRNA might play crucial roles in regulating the type I IFN pathway
or the role of miR-146a could be different in different compartments
among different diseases.
In summary, a simple illustration summarizing the activation of
the type I IFN pathway and related components in Sjögren's syn-
drome is shown in Fig. 1. In general, the pathogenic infection derived
RNA or DNA products activate pDC or glandular epithelial cells to
produce type I IFN through Toll-like receptors. Type I IFN will lead
to BAFF production to activate B cells to produce auto-antibodies
targeting auto-antigens such as Ro/SSA or La/SSB. The formed im-
mune complex of autoantibody and autoantigen will further activate
pDC to produce type I IFN. Other than directly activate T cells, the
type I IFN may activate glandular epithelial cells which may further
attract and activate T cells at disease site. Activated T cells secrete
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Fig. 1. Activation of type I IFN pathway and related events in pSjS.
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other cells and contribute to set up a proinﬂammatory environment.
Immune complex formed by autoantibody and autoantigens which
may be released by apoptotic or necrotic cells induce type I IFN pro-
duction through FCγRII receptor on pDCs. A speciﬁc death event,
NETosis of neutrophils at disease sites may provide nuclear DNA or
proteins as targets for autoantibodies, thus facilitating the formation
of immune complex to further activate pDCs to produce type I IFN.
8. Interventions targeting type I IFN in Sjögren's syndrome
As discussed above, accumulating data provides strong scientiﬁc
evidence that type I IFN activation plays a pivotal role in the patho-
genesis of Sjögren's syndrome. Blockade of type I IFN pathway
might provide clinical beneﬁt to selected patients that have activation
of the type I IFN pathway at disease site. As with all other immuno-
suppressive therapies, it needs to be carefully monitored whether
suppressing the type I IFN signaling pathway might lead to increases
in viral infection in patients. The therapeutic index of targeting
the type I IFN pathway needs to be carefully evaluated in large and
sufﬁciently powered trials. Another key question that needs to be
addressed is whether there is concordance in the activation of the
type I IFN pathway in the peripheral blood and disease site in patients
with pSjS so that the type I IFN signature in the peripheral blood can
serve as a surrogate marker to evaluate the pharmacological effect
of anti-type I IFN therapy in Sjögren's syndrome, and further act as
a potential predictive marker for clinical beneﬁt of therapeutic inter-
ventions. It's also worth noting that there is no effective therapy in
pSjS and there is strong unmet medical need in this disease indica-
tion. Recent clinical trials suggest that a TNF blocker, etanercept, is in-
effective in controlling Sjögren's syndrome. Treatment of etanerceptexacerbated IFN-α and BAFF overexpression, providing a possible ex-
planation for the lack of efﬁcacy of etanercept in Sjögren's syndrome
[73]. Interventions targeting type I IFN signaling pathway have been
examined in several clinical trials (NCT00299819, NCT00962832,
and NCT00541749) for SLE [70,71,140] with the main objective of
evaluating safety and tolerability of the therapeutic interventions.
Larger studies evaluating efﬁcacy (NCT01283139 and NCT01438489)
are currently underway These results will likely shed light on both
the potential effectiveness and patient population that might respond
favorably to anti-type I IFN therapies in SLE, and provide us with some
clue on the potential of anti-type I IFN therapy in pSjS.
Take-home messages
• Type I IFN pathway is activated in involved tissues and periphery in
subjects with Sjögren's syndrome
• Type I IFN induced transcripts or proteins showed utility as robust
marker for type I IFN activation
• Multiple factors including genetic, environmental, epigenetic and
microRNA contribute to the aberrant activation of type I IFN in
Sjögren's syndrome
• Interventions targeting type I IFN pathway might have the potential
to beneﬁt patients with Sjögren's syndrome.
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